Cargando…

Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial

OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Xiaojuan, Chen, Sisi, Zhong, Lu, Li, Yuting, Wu, Chutian, Zhong, Lixian, Chen, Weiwei, Yang, Jinying, Zeng, Jiahua, Tang, Shaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246770/
https://www.ncbi.nlm.nih.gov/pubmed/37293505
http://dx.doi.org/10.3389/fendo.2023.1176256
_version_ 1785055098169196544
author Peng, Xiaojuan
Chen, Sisi
Zhong, Lu
Li, Yuting
Wu, Chutian
Zhong, Lixian
Chen, Weiwei
Yang, Jinying
Zeng, Jiahua
Tang, Shaohui
author_facet Peng, Xiaojuan
Chen, Sisi
Zhong, Lu
Li, Yuting
Wu, Chutian
Zhong, Lixian
Chen, Weiwei
Yang, Jinying
Zeng, Jiahua
Tang, Shaohui
author_sort Peng, Xiaojuan
collection PubMed
description OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM patients were randomly assigned to the CP group or the Glipizide group (G group) in a 2:1 ratio. T2DM-associated metabolic phenotypes, gut microbiota and metabolites including short-chain fatty acids (SCFAs) and bile acids (BAs) were detected. RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT glucose AUC)). Moreover, CP also resulted in the significant improvement in the levels of blood lipid and blood pressure. Notably, the improvement in blood lipid(triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c)) and blood pressure (diastolic blood pressure (DBP)) was significantly greater in the CP group compared with the G group. Furthermore, the liver and kidney function parameters did not significantly change in both CP group and the G group over the 84-day period. Additionally, the enrichment of potentially beneficial bacteria (Faecalibacterium and Akkermansia), SCFAs and unconjugated BAs and the depletion of potential pathogenic bacteria (Prevotella_9) and conjugated BAs were observed in the CP group, while the abundances of the gut microbial were kept stable in the G group after intervention. CONCLUSION: CP displays a more beneficial effect in the alleviation of T2DM-associated metabolic phenotypes than glipizide by regulating gut microbiota and metabolites in T2DM patients, with no significant effects on liver and kidney function.
format Online
Article
Text
id pubmed-10246770
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102467702023-06-08 Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial Peng, Xiaojuan Chen, Sisi Zhong, Lu Li, Yuting Wu, Chutian Zhong, Lixian Chen, Weiwei Yang, Jinying Zeng, Jiahua Tang, Shaohui Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients. METHODS: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM patients were randomly assigned to the CP group or the Glipizide group (G group) in a 2:1 ratio. T2DM-associated metabolic phenotypes, gut microbiota and metabolites including short-chain fatty acids (SCFAs) and bile acids (BAs) were detected. RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT glucose AUC)). Moreover, CP also resulted in the significant improvement in the levels of blood lipid and blood pressure. Notably, the improvement in blood lipid(triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c)) and blood pressure (diastolic blood pressure (DBP)) was significantly greater in the CP group compared with the G group. Furthermore, the liver and kidney function parameters did not significantly change in both CP group and the G group over the 84-day period. Additionally, the enrichment of potentially beneficial bacteria (Faecalibacterium and Akkermansia), SCFAs and unconjugated BAs and the depletion of potential pathogenic bacteria (Prevotella_9) and conjugated BAs were observed in the CP group, while the abundances of the gut microbial were kept stable in the G group after intervention. CONCLUSION: CP displays a more beneficial effect in the alleviation of T2DM-associated metabolic phenotypes than glipizide by regulating gut microbiota and metabolites in T2DM patients, with no significant effects on liver and kidney function. Frontiers Media S.A. 2023-05-24 /pmc/articles/PMC10246770/ /pubmed/37293505 http://dx.doi.org/10.3389/fendo.2023.1176256 Text en Copyright © 2023 Peng, Chen, Zhong, Li, Wu, Zhong, Chen, Yang, Zeng and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Peng, Xiaojuan
Chen, Sisi
Zhong, Lu
Li, Yuting
Wu, Chutian
Zhong, Lixian
Chen, Weiwei
Yang, Jinying
Zeng, Jiahua
Tang, Shaohui
Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title_full Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title_fullStr Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title_full_unstemmed Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title_short Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
title_sort cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in chinese t2dm patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246770/
https://www.ncbi.nlm.nih.gov/pubmed/37293505
http://dx.doi.org/10.3389/fendo.2023.1176256
work_keys_str_mv AT pengxiaojuan cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT chensisi cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT zhonglu cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT liyuting cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT wuchutian cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT zhonglixian cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT chenweiwei cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT yangjinying cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT zengjiahua cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial
AT tangshaohui cyclocaryapaliurusleavesextractsalleviatemetabolicphenotypesinchineset2dmpatientsbymodulatinggutmicrobiotaandmetabolitesaclinicalrandomizedcontrolledtrial